Democritus University of Thrace (DUTH)
Μελέτη παραγόντων της αγγειακής επασβέστωσης σε ασθενείς με διαβητική νεφροπάθεια
Abstract
dc:descriptionVascular calcification is highly prevalent in patients with chronic kidney disease (CKD) and predicts a variety of cardiovascular disease (CVD) events. CVD is the leading cause of morbidity and mortality in patients with kidney failure on dialysis, with a 30-fold higher mortality than the general population, despite adjustment for traditional CVD risk factors. Furthermore, type 2 diabetes mellitus (T2DM) patients present a high prevalence of CVD events due to accelerated vascular calcification, while the underlying pathogenic mechanisms are not completely understood. Thus, it is widely known that high calcification burden is seen in diabetic nephropathy (DN), even in early stages.Genetic and biochemical studies have established matrix Gla protein (MGP) as the first known protein that both in vitro and in vivo acts as a powerful calcification inhibitor. MGP is a vitamin K-dependent protein of 84 amino acids with a molecular weight of 12 kDa, expressed by hypertrophic chondrocytes and vascular smooth muscle cells in the arterial wall. The function of MGP depends on a post-translational γ-glutamyl carboxylation, an essential activation step that rely on the availability of vitamin K. Furthermore, to be fully biologically active, after γ-carboxylation, MGP must undergo phosphorylation on three serine residues. Vitamin K availability is maintained through the vitamin K cycle. In deficiency of vitamin K, MGP is neither carboxylated, nor phosphorylated and therefore remains inactive. The circulating, inactive dephosphorylated, uncarboxyalted form of MGP (dpucMGP) has been repeatedly associated with increased vascular calcification. Moreover, plasma levels of dpucMGP increased progressively with deterioration of renal function in a cohort of patients at different stages of CKD.Several studies have demonstrated that both dietary and genetic factors involved in a set of sequential reactions that guarantee recycling of vitamin K (the vitamin K cycle) can lead to poor vitamin K status and subsequently to reduced function of MGP. Single nucleotide polymorphisms (SNPs) in the key enzyme responsible for the recycling of vitamin K (VKORC1 -vitamin K epoxide reductase complex subunit 1) gene appear to be associated with accelerated calcification of the aorta. More detailed pharmacogenetic studies have demonstrated that carriers of the A allele of VKORC1 -1639G>A polymorphism presented higher function and levels of VKORC1 and subsequently increased vitamin K status and increased function of MGP. Another factor affecting the levels of vitamin K is apolipoprotein E (apoE), which plays an important role in receptor mediated clearance of lipoprotein particles-chylomicron (known carriers of vitamin K) from plasma. The gene encoding MGP has eight SNPs in its promoter and coding regions. Several studies have revealed the importance of the T-138C polymorphism, which lies in a region of the promoter that is essential for transcription in vascular smooth muscle cells.There is a growing body of evidence supporting that higher levels of dp-ucMGP, reflecting vitamin K insufficiency, are strong and independent predictors of adverse outcomes and increased risk for all-cause mortality and both fatal/non-fatal cardiovascular events in various groups of patients.We sought to determine the association between apoE, VKORC1 -1639G > A and MGP T-138C polymorphisms and the plasma levels of the inactive dpucMGP, as well as their effect on carotid intima-media thickness (cIMT) in patients with diabetic nephropathy. We also investigated the distribution of MGP T-138C polymorphism in this group of patients and the predictive value of dpucMGP and MGP T-138C polymorphism in relation to all- cause mortality, cardiovascular mortality and cardiovascular events in patients with DN.VKORC1 -1639G > A, apoE and MGP T-138C polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 40 diabetic patients without nephropathy and 118 patients at different stages of diabetic nephropathy including subjects on hemodialysis. Measurements of cIMT were performed using real-time B-mode ultrasonography. Plasma levels of dpucMGP were determined in a subgroup of 67 patients by ELISA.Mortality and cardiovascular events were assessed during a 7 year follow up. Plasma dpucMGP levels and cIMT values increased significantly with severity of diabetic nephropathy (P<0.0001 and P=0.004 respectively). DpucMGP levels were not associated with any of the three polymorphisms and cIMT. Although VKORC1-1639G> A and apoE polymorphisms were not associated with cIMT, MGP T-138C polymorphism was associated with cIMT in the total population. TT homozygotes for the MGP T-138C polymorphism had higher values of cIMT compared to combined TC and CC genotypes (P=0.006). MGP T-138C polymorphism was a strong independent predictor of cIMT (P<0.0001), after adjustment for several well-known atherosclerosis risk factors. MGP -138TT homozygotes were more frequent in the HD group versus CKD group and controls (P= 0.002). After adjustment for several risk factors, multivariate Cox analysis showed that compared to patients with TC and CC genotypes, subjects with TT genotype presented a significantly higher all-cause and cardiovascular mortality risk [Hazard Ratio (HR) 4.67, 95% Confidence Interval (CI) 1.37-15.94, P= 0.01 and HR 5.07, 95% CI 1.07-24.09, P= 0.04, respectively]. In the subgroup of 67 patients, multivariate Cox analysis showed that high plasma levels of dpucMGP >646 pM are independent risk factor for all-cause mortality [HR 2.97, 95% CI 1.27-6.95, P=0.012], CV mortality - (HR 5.49, 95% CI 1.85-16.33, P=0.002) and non-fatal CV event- (HR 2.07 95% CI 1.00-4.20, P=0.047). Since MGP is an important inhibitor of tissue and VC our study suggests that there may a genetic basis to tissue and VC in diabetic nephropathy.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Roumeliotis, Stefanos
- Ρουμελιώτης, Στέφανος
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45453